Related references
Note: Only part of the references are listed.ELN iMDS flow working group validation of the monocyte assay for chronic myelomonocytic leukemia diagnosis by flow cytometry
Orianne Wagner-Ballon et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2023)
Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation
Xiaona You et al.
BLOOD (2022)
Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML
Margaux Sevin et al.
BLOOD (2021)
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
Daniel J. DeAngelo et al.
NATURE MEDICINE (2021)
RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis
Ryan M. Carr et al.
NATURE COMMUNICATIONS (2021)
A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation
Nico Gagelmann et al.
BLOOD ADVANCES (2021)
Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes
Emma C. St Martin et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia
Antoine N. Saliba et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes
Emma St Martin et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia
Anthony M. Hunter et al.
CLINICAL CANCER RESEARCH (2021)
Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients
Giacomo Coltro et al.
LEUKEMIA (2020)
Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms
Emma C. DiFilippo et al.
LEUKEMIA (2020)
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Pierre Fenaux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia
Mrinal M. Patnaik et al.
BLOOD (2020)
Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Elsa Bernard et al.
NATURE MEDICINE (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Systemic Reprogramming of Monocytes in Cancer
Mate Kiss et al.
FRONTIERS IN ONCOLOGY (2020)
Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes
Mrinal M. Patnaik et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)
Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review
Mrinal M. Patnaik et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)
Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia
Prateek Pophali et al.
BLOOD CANCER JOURNAL (2020)
Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML
Sandrine Niyongere et al.
LEUKEMIA (2019)
Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia
Nolwenn Lucas et al.
LEUKEMIA (2019)
Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients
Tucker Coston et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
Peter Valent et al.
HAEMATOLOGICA (2019)
Practical limitations of monocyte subset repartitioning by multiparametric flow cytometry in chronic myelomonocytic leukemia
Prateek A. Pophali et al.
BLOOD CANCER JOURNAL (2019)
Clonal hematopoiesis in human aging and disease
Siddhartha Jaiswal et al.
SCIENCE (2019)
The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis
Catherine Cargo et al.
BLOOD (2019)
Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review
Sophie Park et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation
Mrinal M. Patnaik et al.
HAEMATOLOGICA (2019)
The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations
Anca Franzini et al.
BLOOD ADVANCES (2019)
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia
V. Santini et al.
LEUKEMIA (2018)
A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1
Sonja Burgstaller et al.
LEUKEMIA & LYMPHOMA (2018)
Clinical Utility of Classical and Nonclassical Monocyte Percentage in the Diagnosis of Chronic Myelomonocytic Leukemia
Chad A. Hudson et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2018)
A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone
Mrinal M. Patnaik et al.
LEUKEMIA (2018)
A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
Pierre Fenaux et al.
LEUKEMIA (2018)
Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates
Katherine Hoversten et al.
LEUKEMIA & LYMPHOMA (2018)
FGFR1 rearranged hematological neoplasms - molecularly defined and clinically heterogeneous
Mrinal M. Patnaik et al.
LEUKEMIA & LYMPHOMA (2018)
Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents
Matthieu Duchmann et al.
EBIOMEDICINE (2018)
Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients
Prateek Pophali et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis
Ayalew Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia
Mohammad Faizan Zahid et al.
LEUKEMIA & LYMPHOMA (2017)
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
S. Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis
M. M. Patnaik et al.
BLOOD CANCER JOURNAL (2017)
Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance
Rangit Vallapureddy et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN
Elias Jabbour et al.
BLOOD (2017)
Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML
Dorothee Selimoglu-Buet et al.
BLOOD (2017)
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
Theo de Witte et al.
BLOOD (2017)
Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis
Chetasi Talati et al.
BLOOD (2017)
Age-related mutations and chronic myelomonocytic leukemia
C. C. Mason et al.
LEUKEMIA (2016)
Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia
Piyanuch Kongtim et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia
Chiara Elena et al.
BLOOD (2016)
When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia
Markus Ball et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)
Eric Padron et al.
CLINICAL CANCER RESEARCH (2016)
Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale
Hanadi Ramadan et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
Chronic Myelomonocytic Leukemia: Focus on Clinical Practice
Mrinal M. Patnaik et al.
MAYO CLINIC PROCEEDINGS (2016)
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents
Jane Merlevede et al.
NATURE COMMUNICATIONS (2016)
Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia
Dorothee Selimoglu-Buet et al.
BLOOD (2015)
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults
Michael R. Savona et al.
BLOOD (2015)
Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
Argiris Symeonidis et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response
Qi Shen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies
Joseph Saliba et al.
NATURE GENETICS (2015)
Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network
Aurelie Caye et al.
NATURE GENETICS (2015)
Anemia as the Main Manifestation of Myelodysplastic Syndromes
Valeria Santini
SEMINARS IN HEMATOLOGY (2015)
ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26
J. Perez Botero et al.
BLOOD CANCER JOURNAL (2015)
Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome (vol 4, e270, 2015)
M. M. Patnaik et al.
BLOOD CANCER JOURNAL (2015)
An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies
E. Padron et al.
BLOOD CANCER JOURNAL (2015)
A Close Association of Autoimmune-Mediated Processes and Autoimmune Disorders with Chronic Myelomonocytic Leukemia: Observation from a Single Institution
Deniz Peker et al.
ACTA HAEMATOLOGICA (2015)
Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study
Emnet A. Wassie et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
Rafael Bejar et al.
BLOOD (2014)
Transcription and enhancer profiling in human monocyte subsets
Christian Schmidl et al.
BLOOD (2014)
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients
M. M. Patnaik et al.
LEUKEMIA (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia
Naval Daver et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
What is a promonocyte?
Barbara J. Bain
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia
Eric Padron et al.
BLOOD (2013)
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia
Esperanza Such et al.
BLOOD (2013)
Clonal architecture of chronic myelomonocytic leukemias
Raphael Itzykson et al.
BLOOD (2013)
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
Raphael Itzykson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes
M. M. Patnaik et al.
LEUKEMIA (2013)
The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia
Alessia Casolaro et al.
PLOS ONE (2013)
Cytogenetic risk stratification in chronic myelomonocytic leukemia
Esperanza Such et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs
Dana E. Rollison et al.
BLOOD (2008)
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
Hagop Kantarjian et al.
CANCER (2008)
FIP1L1-PDGFRA in eosinophilic disorders:: Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature
A. Pardanani et al.
LEUKEMIA RESEARCH (2006)
Detection of c-kit point mutation Asp-816 → Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia
K Sotlar et al.
LEUKEMIA RESEARCH (2002)
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta
JF Apperley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients
F Onida et al.
BLOOD (2002)
Share Paper
